SCIENTIFIC JOURNAL
www.scientificjournal.in
JOURNAL PUBLICATIONS INDEXED IN

www.scientificjournal.in YEAR: 2026 VOLUME: 4 ISSUE: 1 ISSN: 3107-4162

"Revolutionizing Cancer Care: CAR T-Cell Therapy and the Expanding Role of Nurses in Advanced Immunotherapy"

Anisha K Pillai[1]
[1]Lecturer
Government College of Nursing
Ernakulam

DOP: 10/04/2026
DOI 10.5281/zenodo.19492143

Abstract: Chimeric Antigen Receptor (CAR) T-cell therapy represents a groundbreaking advancement in cancer treatment, particularly for hematological malignancies. By genetically modifying a patient's own T lymphocytes to recognize and destroy cancer cells, CAR T-cell therapy has demonstrated remarkable success in cases resistant to conventional treatments. However, this innovative therapy is associated with complex procedures and potentially life-threatening toxicities, necessitating specialized and vigilant nursing care. Nurses play a pivotal role across the continuum of CAR T-cell therapy—from patient selection and education to post-infusion monitoring and long-term follow-up. This review article explores the principles, process, clinical applications, complications, and future prospects of CAR T-cell therapy, while emphasizing the critical contributions of nurses in ensuring patient safety, therapeutic effectiveness, and holistic care. The integration of advanced clinical knowledge, patient-centered communication, and interdisciplinary collaboration is essential for optimizing outcomes in patients undergoing CAR T-cell therapy.

Keywords: *CAR T-cell therapy, immunotherapy, oncology nursing, cytokine release syndrome, neurotoxicity, hematological malignancies, patient care, nursing role, cancer treatment, cellular therapy*

Introduction

Cancer remains one of the leading causes of morbidity and mortality worldwide, prompting continuous advancements in treatment modalities. Traditional approaches such as chemotherapy, radiation, and surgery, although effective in many cases, often fail in relapsed or refractory malignancies. In this context, immunotherapy has emerged as a transformative approach, leveraging the body's immune system to combat cancer.

Among immunotherapeutic strategies, CAR T-cell therapy has gained significant attention due to its ability to target cancer cells with high specificity. This therapy involves extracting T-cells from a patient, genetically engineering them to express chimeric antigen receptors, and reinfusing them to attack tumor cells. Despite its promise, CAR T-cell therapy presents unique challenges, including severe toxicities and logistical complexities, necessitating a highly skilled healthcare team.

Nurses, being at the forefront of patient care, are instrumental in managing the multifaceted aspects of CAR T-cell therapy. Their role extends beyond routine care to encompass patient education, early detection of complications, emotional support, and coordination of care. This article provides a comprehensive overview of CAR T-cell therapy and highlights the indispensable role of nurses in its successful implementation.

Overview of CAR T-Cell Therapy

CAR T-cell therapy is a form of adoptive cell transfer that modifies a patient's immune cells to enhance their cancer-fighting capabilities. The therapy primarily targets

SCIENTIFIC JOURNAL
www.scientificjournal.in
JOURNAL PUBLICATIONS INDEXED IN
www.scientificjournal.in YEAR: 2026 VOLUME: 4 ISSUE: 1 ISSN: 3107-4162

hematological malignancies such as acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma.

The process begins with leukapheresis, where T-cells are collected from the patient's blood. These cells are then genetically engineered in a laboratory to express CARs that recognize specific antigens on cancer cells. Once modified and expanded, the CAR T-cells are infused back into the patient, where they proliferate and attack tumor cells.

Mechanism of Action

CAR T-cells are designed to recognize specific proteins on the surface of cancer cells, such as CD19 in B-cell malignancies. Upon binding to these antigens, CAR T-cells become activated, releasing cytotoxic substances that destroy the target cells. Additionally, they proliferate and persist in the body, providing long-term surveillance against cancer recurrence.

Table 1: Key Components of CAR T-Cell Therapy

Component	Description
T-cell Collection	Leukapheresis to obtain patient's T-cells
Genetic Engineering	Introduction of CAR genes into T-cells
Cell Expansion	Multiplication of modified cells in laboratory
Conditioning Therapy	Chemotherapy prior to infusion
Infusion	Reintroduction of CAR T-cells into patient

Clinical Applications

CAR T-cell therapy has shown significant efficacy in treating hematologic cancers, particularly in patients who have failed multiple lines of therapy. Clinical trials have demonstrated high remission rates in conditions such as B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Emerging research is exploring the application of CAR T-cell therapy in solid tumors, although challenges such as tumor microenvironment and antigen heterogeneity remain barriers to success.

Indications and Patient Selection

Patient selection is critical to the success of CAR T-cell therapy. Candidates typically include individuals with relapsed or refractory malignancies who have exhausted standard treatment options. Comprehensive evaluation, including disease status, organ function, and psychosocial readiness, is essential.

Nurses play a crucial role in assessing patient eligibility, providing education about the procedure, and preparing patients for the therapy journey.

Procedure of CAR T-Cell Therapy

The CAR T-cell therapy process is complex and involves multiple steps over several weeks. Initially, patients undergo leukapheresis for T-cell collection. This is followed by genetic modification and expansion of the cells in specialized laboratories.

Before infusion, patients receive lymphodepleting chemotherapy to enhance the effectiveness of CAR T-cells. The infusion itself is relatively simple but requires close monitoring due to potential adverse reactions.

Table 2: Phases of CAR T-Cell Therapy and Nursing Responsibilities

Phase	Nursing Responsibilities
Pre-collection	Patient education, consent, baseline assessment
Collection	Monitoring during leukapheresis
Pre-infusion	Administer conditioning therapy, prepare patient
Infusion	Monitor vital signs, manage immediate reactions
Post-infusion	Detect complications, provide supportive care

Complications and Side Effects

Despite its effectiveness, CAR T-cell therapy is associated with significant toxicities. The most common and severe complications include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

CRS is characterized by fever, hypotension, and organ dysfunction, resulting from massive cytokine release. ICANS presents with neurological symptoms such as confusion, seizures, and cerebral edema.

Table 3: Major Complications and Management

Complication	Symptoms	Management
Cytokine Release Syndrome	Fever, hypotension, hypoxia	Tocilizumab, supportive care
Neurotoxicity (ICANS)	Confusion, seizures	Corticosteroids, monitoring
Infection	Fever, sepsis	Antibiotics, infection control
Cytopenias	Fatigue, bleeding	Transfusions, growth factors

SCIENTIFIC JOURNAL
www.scientificjournal.in
JOURNAL PUBLICATIONS INDEXED IN
www.scientificjournal.in YEAR: 2026 VOLUME: 4 ISSUE: 1 ISSN: 3107-4162

Role of Nurses in CAR T-Cell Therapy

Pre-Therapy Phase

In the pre-therapy phase, nurses are responsible for patient education, ensuring informed consent, and preparing patients physically and psychologically. They provide detailed information about the therapy, expected outcomes, potential risks, and the importance of follow-up care.

During Therapy

During leukapheresis and infusion, nurses monitor vital signs, manage adverse reactions, and ensure patient comfort. Their vigilance is crucial in identifying early signs of complications.

Post-Therapy Monitoring

Post-infusion care is the most critical phase, as patients are at high risk of developing severe toxicities. Nurses conduct frequent assessments, including neurological evaluations and vital sign monitoring. Early detection and prompt intervention can significantly reduce morbidity and mortality.

Patient and Family Education

Nurses educate patients and caregivers about recognizing symptoms of complications, medication adherence, and lifestyle modifications. This education is essential for early intervention and long-term recovery.

Psychosocial Support

CAR T-cell therapy can be physically and emotionally taxing. Nurses provide emotional support, counseling, and reassurance to patients and their families, helping them cope with anxiety and uncertainty.

Ethical and Legal Considerations

The high cost and limited availability of CAR T-cell therapy raise ethical concerns regarding accessibility and equity. Informed consent is particularly important due to the potential for severe side effects. Nurses play a key role in advocating for patients and ensuring ethical standards are upheld.

Future Perspectives

Advancements in CAR T-cell therapy are focused on improving safety, reducing costs, and expanding its application to solid tumors. Innovations such as “off-the-shelf” CAR T-cells and combination therapies hold promise for the future. The role of nurses will continue to evolve, requiring ongoing education and training to keep pace with technological advancements.

Conclusion

CAR T-cell therapy represents a paradigm shift in cancer treatment, offering hope to patients with otherwise limited options. However, its complexity and potential risks necessitate a multidisciplinary approach, with nurses playing a central role in patient care. From pre-treatment preparation to long-term follow-up, nurses ensure the safe and effective delivery of therapy while addressing the holistic needs of patients. As the field of immunotherapy continues to evolve, the expertise and dedication of nurses will remain integral to its success.

Bibliography

1. June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. *New England Journal of Medicine*, 379(1), 64–73.
2. Maude, S. L., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. *New England Journal of Medicine*, 371(16), 1507–1517.
3. Neelapu, S. S., et al. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory lymphoma. *New England Journal of Medicine*, 377(26), 2531–2544.
4. Lee, D. W., et al. (2019). Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*, 124(2), 188–195.
5. National Comprehensive Cancer Network (NCCN). (2024). *Clinical Practice Guidelines in Oncology*.
6. American Society of Clinical Oncology (ASCO). (2023). *Management of immune-related adverse events*.
7. Oncology Nursing Society (ONS). (2022). *CAR T-cell therapy guidelines for nurses*.
8. Locke, F. L., et al. (2019). Long-term safety and activity of CAR T-cell therapy. *Lancet Oncology*, 20(1), 31–42.
9. Turtle, C. J., et al. (2016). CD19 CAR T cells in B-cell malignancies. *Journal of Clinical Investigation*, 126(6), 2123–2138.

copyright©: Scientific Journal

SCIENTIFIC JOURNAL
www.scientificjournal.in
JOURNAL PUBLICATIONS INDEXED IN
www.scientificjournal.in YEAR: 2026 VOLUME: 4 ISSUE: 1 ISSN: 3107-4162

10. Brudno, J. N., & Kochenderfer, J. N. (2016). Toxicities of CAR T-cell therapy. *Nature Reviews Clinical Oncology*, 13(10), 543–555.

copyright©: Scientific Journal